Xinni Xie1, Xinbo Zhou1, Wei Chen1, Long Long1, Wei Li1, Xiuyan Yang2, Song Li1, Lili Wang3. 1. Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China. 2. Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China; School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, China. 3. Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China. Electronic address: wangll63@126.com.
Abstract
BACKGROUND: Selective PPARγ modulators (sPPARγM) retains insulin sensitizing activity but with minimal side effects compared to traditional TZDs agents, is thought as a promising strategy for development of safer insulin sensitizer. METHODS: We used a combination of virtual docking, SPR-based binding, luciferase reporter and adipogenesis assays to analyze the interaction mode, affinity and agonistic activity of L312 to PPARγ in vitro, respectively. And the anti-diabetic effects and underlying molecular mechanisms of L312 was studied in db/db mice. RESULTS: L312 interacted with PPARγ-LBD in a manner similar to known sPPARγM. L312 showed similar PPARγ binding affinity, but displayed partial PPARγ agonistic activity compared to PPARγ full agonist pioglitazone. In addition, L312 displayed partial recruitment of coactivator CBP yet equal disassociation of corepressor NCoR1 compared to pioglitazone. In db/db mice, L312 (30 mg/kg·day) treatment considerably improved insulin resistance with the regard to OGTT, ITT, fasted blood glucose, HOMA-IR and serum lipids, but elicited less weight gain, adipogenesis and hemodilution compared with pioglitazone. Further studies demonstrated that L312 is a potent inhibitor of CDK5-mediated PPARγ phosphorylation and displayed a selective gene expression profile in epididymal WAT. CONCLUSIONS: L312 is a novel sPPARγM. GENERAL SIGNIFICANCE: L312 may represent a novel lead for designing ideal sPPARγM for T2DM treatment with advantages over current TZDs.
BACKGROUND: Selective PPARγ modulators (sPPARγM) retains insulin sensitizing activity but with minimal side effects compared to traditional TZDs agents, is thought as a promising strategy for development of safer insulin sensitizer. METHODS: We used a combination of virtual docking, SPR-based binding, luciferase reporter and adipogenesis assays to analyze the interaction mode, affinity and agonistic activity of L312 to PPARγ in vitro, respectively. And the anti-diabetic effects and underlying molecular mechanisms of L312 was studied in db/db mice. RESULTS:L312 interacted with PPARγ-LBD in a manner similar to known sPPARγM. L312 showed similar PPARγ binding affinity, but displayed partial PPARγ agonistic activity compared to PPARγ full agonist pioglitazone. In addition, L312 displayed partial recruitment of coactivator CBP yet equal disassociation of corepressor NCoR1 compared to pioglitazone. In db/db mice, L312 (30 mg/kg·day) treatment considerably improved insulin resistance with the regard to OGTT, ITT, fasted blood glucose, HOMA-IR and serum lipids, but elicited less weight gain, adipogenesis and hemodilution compared with pioglitazone. Further studies demonstrated that L312 is a potent inhibitor of CDK5-mediated PPARγ phosphorylation and displayed a selective gene expression profile in epididymal WAT. CONCLUSIONS:L312 is a novel sPPARγM. GENERAL SIGNIFICANCE: L312 may represent a novel lead for designing ideal sPPARγM for T2DM treatment with advantages over current TZDs.
Authors: Maurizio Vitti; Giovanna Di Emidio; Michela Di Carlo; Gaspare Carta; Andrea Antonosante; Paolo Giovanni Artini; Annamaria Cimini; Carla Tatone; Elisabetta Benedetti Journal: PPAR Res Date: 2016-07-31 Impact factor: 4.964
Authors: Marieli Mariano Gonçalves Dias; Fernanda Aparecida Heleno Batista; Thais Helena Tittanegro; André Gustavo de Oliveira; Albane Le Maire; Felipe Rafael Torres; Helder Veras Ribeiro Filho; Leonardo Reis Silveira; Ana Carolina Migliorini Figueira Journal: Front Endocrinol (Lausanne) Date: 2020-11-27 Impact factor: 5.555
Authors: Chathyan Pararasa; John Ikwuobe; Shahjahan Shigdar; Alexis Boukouvalas; Ian T Nabney; James E Brown; Andrew Devitt; Clifford J Bailey; Stuart J Bennett; Helen R Griffiths Journal: Aging Cell Date: 2015-11-02 Impact factor: 9.304